USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

FirstHealth of the Carolinas will offer free lung cancer screenings using its mobile Lung Bus at FirstHealth Lee Campus located at 2919 Beechtree Drive in Sanford from 8:30 a.m. to 12:30 p.m. on ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...

The fight against cancer in the country has received another major boost after Nairobi West Hospital announced that it had ...